Funding

MINIRAD project – interregional PHRC 

Laisser un commentaire / Funding / Par

🎉We are pleased to announce that our MINIRAD project has been selected for funding under the 2025-2026 interregional PHRC (Hospital Clinical Research Program). 🔬 This multicenter project, entitled « Radial endoscopic ultrasound miniprobe as a first-line strategy for the diagnosis of pulmonary nodules and masses with bronchial signs: an open-label, randomized superiority trial, » aims to evaluate an innovative diagnostic strategy in pulmonology. 🎯 The objective is twofold: to improve diagnostic performance while enhancing patient safety, notably through an expected reduction in the risk of pneumothorax during diagnostic procedures. 🙏  Many thanks to all the investigators, partners, and research support teams who contributed to the development of this project. Congratulations to Laurent Plantier for his coordination.

ANR fundings 2025

Funding / Par

😀 Great ANR-2025 results for the CEPR!! 👏 Congratulations to Christophe Paget and Nathalie Heuzé-Vourc’h for their participation in the ALS-IMMUNE (CE17) and PETREL (CE18) programs! 👏 Congratulations to Noémie Alphonse and Benoît Briard for obtaining their Young Researcher grants (ANR JCJC, CE15), Ti-LAB and AspSTAT5 respectively. This bodes well for exciting discoveries and a new dynamic for our teams!

4-year ANR funding obtained (PROJECT COORDINATION: M. Si-Tahar): Development of Succinate-based analogues and formulations against SARS-CoV-2 and influenza viruses-induced respiratory infections – (SuccesS)

Funding / Par

The emergence of pandemic respiratory viruses is a major concern. Those viruses include coronaviruses such as SARS-CoV-2 and influenza A viruses (IAV). There are currently no efficient drugs against coronaviruses and the efficacy of anti-IAV drugs is disputed. Vaccination should constitute the most preventive strategy. However, the intrinsic antigenic drift of IAV impairs vaccine protection. Besides, previous coronaviruses crises showed that poorly neutralizing antibodies developed after vaccination may enhance subsequent infection. Current vaccine hesitancy also remains a barrier to full population inoculation against SARS-CoV-2. Our ANR project is thus aimed to develop an innovative metabolic therapy against those two viruses, delivered via the pulmonary route, based on (i) recent evidence that metabolites are key effectors of the host antimicrobial response and (ii) our preliminary data which identified two metabolites with anti-IAV and anti-SARS-CoV-2 antiviral activity. source : https://anr.fr/Projet-ANR-21-CE18-0061